TNFRSF10B and melanoma: DR5 is overexpressed in various cancers, including liver cancer, melanoma, and pancreatic cancer, while its presence in normal tissues is significantly lower.[45, 46, 47] DR5 agonist scFv containing EV hybrids' binding affinity to DR5 were assessed using A375 melanoma cell lines with DR5 knockout (KO), wild type (WT), and overexpression (OExp).